Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shikimate dehydrogenase (SDH) is an NAD(P)H-dependent oxidoreductase enzyme that catalyzes the reversible reduction of 3-dehydroshikimate to shikimate, using NADPH as a cofactor. This reaction constitutes the fourth step in the shikimate pathway, which is essential for the biosynthesis of aromatic amino acids—phenylalanine, tyrosine, and tryptophan—in plants, bacteria, fungi, algae, and some parasites. Animals and humans lack this pathway, making SDH an attractive target for herbicides and antimicrobial agents.
Inhibition of shikimate dehydrogenase activity, blocking the shikimate pathway and ultimately inhibiting the synthesis of aromatic amino acids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shikimate dehydrogenase (SDH).